Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy

NCT00245765 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00245765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00245765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
November 30, 2006
Enrollment
176 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic plaque psoriasis